Magna-Lab nabs distribution deal

Article

Magna-Lab has added to its stableof distribution partners by signing a deal this month with BetaNumerics for global sales and marketing of the company's Magna-SL0.3-tesla extremity scanner. The deal complements a similar agreementreached with Elscint

Magna-Lab has added to its stableof distribution partners by signing a deal this month with BetaNumerics for global sales and marketing of the company's Magna-SL0.3-tesla extremity scanner. The deal complements a similar agreementreached with Elscint (SCAN 12/14/94).

Beta Numerics, of Canandaigua, NY, was formed recently to placemedical equipment at clinical sites on a fee-for-service basis.Its management team is headed by chairman Coy Eklund, formerlychairman of Equitable Life Assurance Society, and medical imagingveteran John Roberts, who serves as president.

Under the agreement between the firms, Beta Numerics will handledistribution of Magna-SL in Japan, India, Mexico, Singapore andGreece. These territories are not covered by Magna-Lab's Elscintdeal.

In addition, Beta Numerics has exclusive worldwide rights tofee-for-service placements of Magna-SL. Beta Numerics will alsohave worldwide distribution rights to a mobile version of Magna-SLin return for funding development of the scanner, according toMagna-Lab president John Haytaian.

As part of the agreement, Beta Numerics advanced $400,000 toMagna-Lab as payment for the first delivery of a Magna-SL system,which is being placed in aSan Antonio hospital on a fee-for-servicebasis.

The 10-year agreement requires minimum purchases by Beta Numericsof eight scanners in 1995, 16 scanners in the second year and24 scanners a year in the third through the tenth year. If theminimum targets are met, the deal would be worth $80 million toMagna-Lab.

In other Magna-Lab news, the Hicksville, NY, company met withrepresentatives from the NASDAQ stock exchange on Dec. 15 to discussthe firm's listing. NASDAQ informed Magna-Lab in November thatit may be out of compliance with NASDAQ listing requirements basedon the company's second-quarter results.

The meeting with NASDAQ went well and Magna-Lab believes thatit will maintain its listing, according to Haytaian. Magna-Labexpects to get final word on NASDAQ's decision by the middle ofJanuary.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.